David Wallace
Executive Editor
Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.
Latest From David Wallace
Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
BGMA Warns That Policy Vacuum Risks UK Becoming ‘Supply Backwater’
With a UK general election looming, local generics and biosimilars industry association the BGMA has warned that the country will be “deprioritized as a supply market” without a more focused and supportive policy environment for the off-patent sector.
Meitheal Prepares For Major US Injectables Push
Meitheal Pharmaceuticals says it is preparing to launch “up to 20 new products” this year in the US following a recent expansion of its generic injectables portfolio.
‘Imperfect Compromise’ On EU Pharma Legislation Still Offers Progress
Reacting to the latest position on the EU pharma legislation overhaul adopted by a European Parliament committee – including changes to previous proposals on regulatory data protection – Medicines for Europe said that the “imperfect” compromise nevertheless offers improvements.
Leading The Charge On US Humira Competition, Organon Sets Out Strategy
With US biosimilar competition to Humira slow to start in 2023, Organon’s US biosimilars head Jon Martin talks about how the firm is pushing forward to ramp up progress on adalimumab this year, as well as longer-term opportunities.
Aspire Eyes UK Opportunity From GSK Dropping Fluticasone
Aspire Pharma says that its UK launch of fluticasone propionate 400mcg 1mg/ml nasal drops “further establishes Aspire as a premier specialty generics business,” noting that the product is hitting the market in the wake of GSK pulling out, “leading to a possible short supply for patients.”